

# Vardhaman Laboratories Limited

REGD. OFFICE : High School Road, P.O. Box 184, SANGLI 416416

Tel : (0233) 2623886 E-mail : vardhaman.lab@gmail.com

L85195PN1985PLC036017

19<sup>th</sup> February, 2019.

To,

**The Secretary,**

Department of Corporate Services,  
Bombay Stock Exchange Limited,  
Floor 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001

**Sub.:- Outcome of Board Meeting**

**Ref.:- Scrip Code 524796**

Sir,

With reference to the above subject, this is to inform you that the Board of Directors of the Company at its meeting held on 14<sup>th</sup> February, 2019, considered the following:-

1. Approval of Unaudited Financial Results of the Company for the quarter ended December 31, 2018.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully

For **VARDHAMAN LABORATORIES LIMITED**



**Sumedh Shah**

Director

DIN: 00321474

**AGRAWAL NAREDI & CO.**  
**CHARTERED ACCOUNTANTS**  
391, NARAYAN PETH, PUNE- 411 030

**INDEPENDENT AUDITOR'S REVIEW REPORT**

To  
The Board of Directors  
Vardhaman Laboratories Limited

We have reviewed the accompanying statement of unaudited financial results of **Vardhaman Laboratories Limited** for the quarter ended 31<sup>st</sup> December, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 14<sup>th</sup> February, 2019. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agrawal Naredi & Co.  
**Chartered Accountants**  
Firm Registration No. 122480W.

*RS*

**Radhesham Agrawal**  
Partner  
Membership No. 118336



Date: 14<sup>th</sup> February, 2019  
Place: Pune

# Vardhaman Laboratories Limited

Statement of Standalone Unaudited Financial Results for the Nine months ended 31st December, 2018							(Rs. )
PARTICULARS		Quarter Ended			Nine Month Ended		Year Ended
		31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income From Operations</b>						
	(a)	Revenue from Operations	-	-	-		
	(b)	Other Income	-	-	1.08	2.92	3.54
	<b>Total Income</b>		-	-	<b>1.08</b>	-	<b>2.92</b>
2	Expenditure						
	(a)	Cost of Materials Consumed	-	-	-	-	-
	(b)	Purchase of Stock-in-Trade	-	-	-	-	-
	(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade					
	(d)	Excise Duty					
	(e)	Employees Benefits expenses					
	(f)	Finance Cost					
	(g)	Depreciation and amortisation expenses					
	(h)	Other Expenses	0.61	0.50	0.79	1.11	5.87
	<b>Total Expenses</b>		<b>0.61</b>	<b>0.50</b>	<b>0.79</b>	<b>1.11</b>	<b>5.87</b>

# Vardhaman Laboratories Limited

3	Profit/(Loss) before exceptional and extraordinary item and tax (1-2)	(0.61)	(0.50)	0.29	(1.11)	(2.95)	(3.67)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before tax (3+4)	(0.61)	(0.50)	0.29	(1.11)	(2.95)	(3.67)
6	Tax Expenses - Current Tax	-	-	-	-	-	-
	- Deferred Tax	-	-	-	-	-	-
7	<b>Net Profit/(Loss) for the period (5-6)</b>	(0.61)	(0.50)	0.29	(1.11)	(2.95)	(3.67)
8	Other comprehensive Income						
	- Items that will be reclassified to profit or loss	-	-	-	-	-	-
	- Items that will not be reclassified to profit or loss	-	-	-	-	-	-
9	Total Comprehensive Income (7+8) (Comprising profit and Other Comprehensive Income for the period)	(0.61)	(0.50)	0.29	(1.11)	(2.95)	(3.67)
10	Paid-up equity share capital (Face Value of Rs.10/- per share)	412.47	412.47	412.47	412.47	412.47	412.47
11	Other Equity	-	-	-	-	-	-
12	Earnings per share ( of Rs.10/- each ) ( not annualised )						
	(a) Basic	-0.01	-0.01	0.01	-0.03	-0.07	-0.09
	(b) Diluted	(0.01)	(0.01)	0.01	(0.03)	(0.07)	(0.09)

# Vardhaman Laboratories Limited

Notes:	
1	The above results have been reviewed and recommended for adoption by the Audit Committee to the Board of Directors and have been approved by the Board of Directors at its meeting held on 14th February, 2019. The Statutory Auditors have carried out limited review of the above financial results.
2	The financial results are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Sections 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards Amendment) Rules, 2016 and other accounting principles generally accepted in India.
3	The Company has only one segment which is pharmaceuticals. Therefore disclosure relating to segment is not applicable and accordingly not made.
4	Previous Period's figures have been regrouped and reclassified, wherever necessary.
5	Provision for income tax shall be made at the end of the year
6	The company did not have investor complain pending as on quarter 31st December, 2018

For **VARDHAMAN LABORATORIES LIMITED**



**Sumedh Shah**  
Director  
DIN: 00321474

**Date: February 14, 2019**

**Place: Sangli**